Aduro Biotech | Discovering and Developing Immunotherapies.

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight diseases

STING Pathway

APRIL Pathway

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2018 Annual Report

Recent News

September 04, 2019 Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

September 03, 2019 Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

August 01, 2019 Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?